

2002 Subscriptions

Regular mail: CHF 60

or USD 37

Priority mail CHF 70

or USD 43 25% discount for

two or more

subscriptions

Binders CHF 18 or USD 11

Order online at:

www.wipo.int/ebookshop

NEWSLETTER

July 2002 No. 07/2002

MOST FREQUENT PCT USERS IN 2001

In 2001, 190 applicants accounted for 28.4% (28,320) of the 99,606 international applications published, each with 50 or more applications published (as compared with 155 applicants with 50 or more applications published in 2000). Of these 190 applicants, 45.8% were from the United States of America, 19.5% from Japan, and 10.0% from Germany. There were 66 applicants in each of whose names more than 100 international applications were published. Koninklijke Philips Electronics N.V was the largest PCT user, with 1,458 international applications published in 2001, which is nearly 200 more applications than the largest PCT user in 2000. It is interesting to note that, for the first time since the list of most frequent users was first published in the PCT Newsletter six years ago, an applicant from a developing country, "Shanghai Biowindow Gene Development Inc." from China, is in the top ten with as many as 665 applications published in 2001.

Note that the list of most frequent PCT users contains only the first-named applicants in the applications concerned. Note also that certain legal entities are listed separately from other legal entities with which they may be affiliated.

The list on pages 9 to 12 indicates the applicants by the number of applications published. A second list on pages 12 to 15 indicates the applicants in alphabetical order.

BUDAPEST TREATY

Accession by the former Yugoslav Republic of Macedonia

On 30 May 2002, the former Yugoslav Republic of Macedonia deposited its instrument of accession to the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. That Treaty will enter into force with respect to the former Yugoslav Republic of Macedonia on 30 August 2002.

NEW FEATURE: PCT QUIZ

The PCT Newsletter will now include a new regular feature to test your PCT knowledge. Please do not send your answers to WIPO though—the answer will be given in the next issue of the PCT Newsletter. Note that there may be more than one correct answer in respect of certain questions. The first question appears on page 3.

INSIDE THIS ISSUE

| PCT Information |
|--------------------------|
| update 2-6 |
| PCT Quiz 3 |
| Practical advice 6 |
| New PCT materials on |
| the Internet 6-7 |
| PCT publications 7 |
| PCT seminar calendar 7-8 |
| Lists of most frequent |
| PCT users in 2001 9-15 |
| PCT fee tables 16-19 |
| PCT Contracting |
| States and two-letter |
| codes20 |
| |

PCT INFORMATION UPDATE

BE Belgium (requirements concerning agent)

There has been a change in the requirements of the Industrial Property Office (Belgium) as to whether an agent is required by it as receiving Office, and as to who can act as agent before it, as follows:

is an agent required by the receiving Office?

no, if the applicant resides in a member State of the European Communities

yes, if he is a non-resident

Selection of PCT MATERIALS ON INTERNET

(http://www.wipo.int/pct/en/)

Welcome page, with links to what's new on the site PCT Information Service PCT filing

- Basic Facts about the PCT
- Forms
- Fees
- Direct filing of PCT applications with the International Bureau as PCT receiving Office

- PCT Applicant's Guide PCT-EASY

PCT E-filing (PCT-SAFE)

PCT legal texts and guidelines - About the Treaty

- Texts of the Patent Cooperation Treaty, Regulations and Administrative Instructions and search facility for Articles under PCT
- PCT Receiving Office Guidelines
- PCT International Search Guidelines
- PCT International Preliminary Examination Guidelines
- PCT Contracting States
- Reservations and incompatibilities
- Notifications concerning non-applicability of modified time limit under PCT Article 22(1)

PCT legal text index

PCT Gazette

PCT news

- PCT Newsletter (Nos. 01/1997–07/2002);
 Practical Advice published in the PCT Newsletter between March 1994 and December 1996 and search facility for all Practical Advice
- PCT Press Releases/Updates

- The PCT in 2001

Seminar calendar and seminar materials:

seminar documents: February 2002 (English);
 April 2002 (French and German); May 2001 (Spanish);

PCT meetings (documents):

- Committee (21–25 May 2001; 1–5 July 2002) and Working Group on Reform of the PCT (12–15 November 2001; 29 April–3 May 2002)
- PCT Assembly: 1978-2001

PCT INFORMATION SERVICE

Telephone: (41–22) 338 83 38 Fax: (41–22) 338 83 39 E-mail: pct.infoline@wipo.int who can act as agent?

any person registered to practice as a representative before the Office (the list of registered representatives is furnished free of charge on request) or any representative authorized to practice in a member State of the European Communities and who is a national of a member State of the European Communities

any attorney-at-law registered on the list of Belgian attorneys-at-law or on the list of probationary attorneys, or authorized to practice in Belgium by law or an international convention or any attorney who is a national of a member State of the European Communities and is authorized to practice in a member State of the European Communities

(Updating of *PCT Applicant's Guide*, Vol. I/B, Annex C (BE))

CA Canada (fees; special requirements)

There has been a change in the time limit for payment of the maintenance fee, payable to the Canadian Patent Office as designated or elected Office. The footnote relating to that fee (the reference for which appears under "National fee" in the *PCT Applicant's Guide*, Vol. II/A, National Chapter, Summary (CA)) should now read as follows:

"where PCT Article 22 or 39(1) applies: this fee is due within 24 months from the international filing date or within 30 months from the priority date if that time limit expires later or, provided the applicant pays the additional fee for late entry into the national phase, within 42 months from the priority date"

There has also been a change in the time limit for compliance by the applicant with the special requirements under PCT Rule 51*bis* before the Office as designated or elected Office. The footnote relating to all of the special requirements (the reference to which appears under "Special requirements of the Office (PCT Rule 51*bis*)") should now read as follows:

"where PCT Article 22 or 39(1) applies: if not complied with within 36 months from the priority date or, provided that the applicant pays the additional fee for late entry into the national phase, if not complied with within six months after

PCT QUIZ

When is it possible to correct an erroneous or incomplete priority claim in an international application?

- (a) At any time during the international phase.
- (b) At any time before the date of international publication of the application.
- (c) Within four months from the international filing date.

[Answer in next issue]

the applicant has performed the acts necessary for entry into the national phase, the application will be deemed abandoned"

(Updating of *PCT Applicant's Guide*, Vol. II/A, National Chapter, Summary (CA))

CR Costa Rica (special requirements; time limit for entry into the national phase)

There have been changes in the special requirements under PCT Rule 51 bis of the Registry of Intellectual Property (Costa Rica) as designated (or elected) Office. The consolidated list of special requirements is as follows:

- name and address of the inventor if they have not been furnished in the "Request" part of the international application¹
- instrument of assignment or transfer of the right to the application¹
- evidence of entitlement to claim priority where the applicant is not the applicant who filed the earlier application¹
- evidence concerning non-prejudicial disclosures or exceptions to lack of novelty, such as disclosures resulting from abuse, disclosures at certain exhibitions and disclosures by the applicant during a certain period of time¹
- appointment of an agent or address for notification in Costa Rica
- translation of the international application or any document relating to it to be furnished in two copies
- verified translation of the international application, where deemed necessary

verified translation of the priority document²

- 1. this requirement may be satisfied if the corresponding declaration has been made in accordance with PCT Rule 4.17.
- 2. only if the validity of the priority claim is relevant to the determination of whether the invention concerned is patentable.

(Updating of *PCT Applicant's Guide*, Vol. II/A, National Chapter, Summary (CR)) See also "Time limits for entry into the national phase," below.

DZ Algeria (time limit for entry into the national phase)

See "Time limits for entry into the national phase," below.

IN India (time limit for entry into the national phase)

See "Time limits for entry into the national phase," below.

KE Kenya (fees)

The amounts of the following fees, payable to the Kenya Industrial Property Institute as receiving Office, have changed:

transmittal fee: see Table I(a) fee for priority document: USD 100 or equivalent in KES

The amounts of the following national fees, payable to the Office as designated (or elected) Office, have changed:

for patent:

national processing

ee: USD 150

annual fees for the second and subsequent

years, per year¹ [no change]:

for utility model:

national processing

fee: USD 50

annual fees for the second and subsequent

years, per year¹ USD 50

1. Late payment of annual fees is permitted in certain circumstances subject to the payment of a surcharge. The annual fee for the second year is due upon entry into the national phase.

((Updating of *PCT Applicant's Guide*, Vol. I/B, Annex C (KE), and Vol. II/B, National Chapter, Summary (KE))

LK Sri Lanka (Internet address)

The National Intellectual Property Office (Sri Lanka) has notified its Internet address,

as follows:

Internet: http://nipo.sliit.lk (Updating of *PCT Applicant's Guide*, Vol. I/B, Annex B1 (LK))

MD Republic of Moldova (furnishing of copies of international applications)

The State Agency on Industrial Property Protection (Republic of Moldova) has changed its requirement as to whether a copy of the international application is required for entry into the national phase before it as designated (or elected) Office, as indicated below:

is a copy of the international application required?

the applicant should only send a copy of the international application if he/she has not received Form PCT/IB/308 and the Office has not received a copy of the international application from the International Bureau under PCT Article 20. This may be the case where the applicant expressly requests an earlier start of the national phase under PCT Article 23(2).

(Updating of *PCT Applicant's Guide*, Vol. II/B, National Chapter, Summary (MD))

MX Mexico (fees)

The amounts of the following national fees, payable to the Mexican Institute of Industrial Property as designated (or elected) Office, have changed:

for patent:

filing fee: MXP 4,732.50¹

MXP $3,157.50^2$

for utility model:

filing fee: MXP 1,372.50¹ MXP 915.00²

- 1. Payable where the national phase is entered under PCT Article 22. This fee includes a 25% reduction based on the establishment of an international search report.
- 2. Payable where the national phase is entered under PCT Article 39(1). This fee includes a 50% reduction based on the establishment of an international preliminary examination report.

((Updating of *PCT Applicant's Guide*, Vol. II/B, National Chapter, Summary (MX))

US United States of America (location)

The location of the United States Patent and Trademark Office should now be indicated as follows:

location:

2011 South Clark Place Crystal Plaza 2 Arlington Virginia 22202, USA

(Updating of *PCT Applicant's Guide*, Vol. I/A, Annex B1 (US))

Viet Nam (types of protection; competent International Searching and Preliminary Examining Authorities; fees; time limit for entry into the national phase)

The National Office of Industrial Property (Viet Nam) has notified the International Bureau that the type of protection available via the PCT previously indicated as a "utility model" is in fact a "patent for utility solution." The consolidated list of the types of protection available via the PCT is now as follows:

patents, patents for utility solution

The Office, in its capacity as receiving Office, has specified, as from 1 August 2002, for international applications in English and filed by nationals and residents of Viet Nam with the National Office of Industrial Property (Viet Nam) as receiving Office, the Korean Intellectual Property Office*, in addition to the Australian Patent Office, the Austrian Patent Office, the European Patent Office**, the Russian Patent Office and the Swedish Patent Office, as a competent International Searching and Preliminary Examining Authority.

- * the Korean Intellectual Property Office is competent only for international applications in English where the international application or the demand for international preliminary examination is filed on or after 1 August 2002.
- ** the European Patent Office is a competent International Preliminary Examining Authority only if the international search is being or has been performed by the Austrian Patent Office, the European Patent Office or the Swedish Patent Office.

New amounts of national fees, payable to the Office as designated (or elected) Office, have been introduced as follows:

filing fee: [no change] additional fee for each sheet in excess of five: [no change]

fee for priority claims,

per priority [no change] additional fee for each object in excess

of one:
for patent:
USD 30

for patent for utility solution: USD 20

fee for requesting substantive examination:

for patent: USD 100 for patent for utility solution: USD 90

(Updating of *PCT Applicant's Guide*, Vol. I/A, Annex B1 (VN), Vol. I/B, Annex C (VN), and Vol. II/C, National Chapter, Summary (VN))

See also "Time limits for entry into the national phase," below.

ZA South Africa (fees)

As from 1 August 2002, there will be a change in the equivalent amounts of the following fees payable in ZAR to the South African Patents and Trade Marks Office as receiving Office, as well as a change in the equivalent amount of the PCT-EASY fee reduction:

basic fee, fee per sheet in excess of 30, designation fee and PCT-EASY fee reduction: see Table I(a)

(Updating of *PCT Applicant's Guide*, Vol. I/B, Annex C (ZA))

Search fee (European Patent Office, Swedish Patent Office, United States Patent and Trademark Office)

As from 15 August 2002, there will be a change in the equivalent amount payable in NOK for an international search carried out by the European Patent Office and in the corresponding amount payable in NOK for an international search carried out by the Swedish Patent Office, as indicated in Table I(b).

As from 1 September 2002, there will be a change in the equivalent amount payable in ZAR for an international search carried out by the United States Patent and Trademark Office, as indicated in Table I(b).

(Updating of *PCT Applicant's Guide*, Vol. I/B, Annex D (EP, SE, US))

Sequence listings—requirements of International Searching and Preliminary Examining Authorities and types of electronic medium accepted by those Authorities

The following Offices, which have notified the International Bureau that, under PCT Rule 13*ter*.1, they require that a nucleotide and/or amino acid sequence listing be furnished in computer readable form, have

specified that they require the following types of electronic medium:

Austrian Patent Office*:

Diskette CD-ROM

* additionally, a printed version on paper is required

Australian Patent Office:

the entire printable copy of the sequence listing and identifying data should be contained within one text file on a single 3½" formatted 1.44 MB diskette or a single standard (ISO 9660) CD-ROM or CD-R

Spanish Patent and Trademark Office:

Diskette CD-ROM

Swedish Patent Office:

Diskette

United States Patent and Trademark Office:

Diskette: 3.50 inch, 1.44 MB storage; 3.50 inch, 720 KB storage; 5.25 inch, 1.2 MB storage; 5.25 inch, 360 KB storage

Magnetic tape: 0.5 inch, up to 24,000 feet; Density: 1,600 or 6,250 bits per inch, 9 track; Format: Unix tar command; specify blocking factor (not "block size"); Line Terminator: ASCII Carriage Return plus ASCII Line Feed 8mm Data Cartridge: Format: Unix tar command; specify blocking factor (not "block size"); Line Terminator: ASCII Carriage Return plus ASCII Line Feed Compact disc: Format ISO 9660 or High Sierra Format

Magneto Optical Disk: Size/Storage Specifications: 5.25 inch, 640 MB

(Updating of *PCT Applicant's Guide*, Vol. I/B, Annex D (AT, AU, ES, SE, US))

Time limits for entry into the national phase (Algeria, Costa Rica, India, Viet Nam)

The Algerian National Institute of Industrial Property, the Registry of Intellectual Property (Costa Rica) and the National Office of Industrial Property (Viet Nam) have notified, respectively, a change in the time limit applicable for entry into the national phase under PCT Article 22(3) before them as designated Offices. The new time limit in all cases, applicable as from 1 April 2002, is 31 months from the priority date.

The Patent Office (India) has notified a change in the time limit applicable for entry into the national phase under PCT Article 22(3) before the Office as a designated Office. The new time limit, applicable as from 7 May 2002, is 31 months from the priority date.

(Updating of *PCT Applicant's Guide*, Vols. II/A, B and C, National Chapters, Summaries (CR, DZ, IN and VN) and *PCT Newsletter* No. 03/2002, page 6 (table of time limits for entering national/regional phase under PCT Chapters I and II))

PRACTICAL ADVICE

Using an address for correspondence

Q: I appointed a US agent while living in the United States of America (US) to act on my behalf in respect of an international application, for which I am sole applicant, that was filed with the United States Patent and Trademark Office (USPTO) as receiving Office. Recently I left the US and moved to Australia, and since it seemed impractical to have an agent in the US, I revoked the appointment of that agent, hoping, for the sake of convenience, to find an Australian patent agent who I could appoint to take over as agent for the international application. But now I am wondering whether it is possible for me to appoint such an agent to act before the USPTO as receiving Office?

A: According to PCT Rule 90.1(a): "A person having the right to practice before the national Office with which the international application is filed [emphasis added]... may be appointed by the applicant as his agent to represent him before the receiving Office, the International Bureau, the International Searching Authority and the International Preliminary Examining Authority." Thus, in order to be validly appointed, the agent must have the right to practice before the receiving Office, which in this case is the USPTO. That Office has specified that only patent attorneys and patent agents registered to practice before the USPTO may act as agents before it. It is therefore unlikely that there are many Australian patent agents who could be validly appointed before the USPTO, but you may nevertheless wish to check the register at the USPTO (see www.uspto.gov/web/offices/ dcom/olia/oed/roster/index.html).

From a practical viewpoint, since you are sole applicant and you have revoked the appointment of the earlier agent, there is a feature of the PCT system that you could make use of that would allow you to arrange for all correspondence to be sent to the person in Australia who you would like to help you with your application (see PCT Rule 4.4(d)). To do this you should make a request for a change under PCT Rule 92bis requesting that a change in your country of residence be recorded, and also that all future documents and correspondence relating to the international application be sent to the person of your choice as "an address for correspondence." That person would not, however, be entitled to act on behalf of the applicant in respect of the application and would merely receive all correspondence which would normally be addressed to you as applicant. That person would not have the right to sign any papers, including letters, on your behalf-any such papers would have to be signed by you.

If you had known at the time of filing the international application that you were going to move to another country, and you had filed the application with the International Bureau as receiving Office (RO/IB), you could initially have appointed an agent in the US, revoked that appointment when you moved to Australia, made a request for recording a change of residence of the applicant under PCT Rule 92bis, and then validly appointed an Australian agent (provided that he/she was entitled to practice before the Australian Patent Office). In this case, the new appointment would have been valid due to the fact that, according to PCT Rule 83.1bis(a), any person who has the right to practice before the national Office of, or acting for, a Contracting State of which the applicant is a resident or national is entitled to practice in respect of the international application before RO/IB (as opposed to a person having the right to practice before the national Office with which the international application was filed (see PCT Article 49) in the case of other receiving Offices). (See also the practical advice in *PCT Newsletter* No. 07/1996 concerning entitlement to practice before RO/IB.)

For information on who can act as agent before each receiving Office, see the *PCT Applicant's Guide*, Vol. I/B, Annex C.

NEW PCT MATERIALS ON THE INTERNET (http://www.wipo.int/pct/en/)

The modifications to the Administrative Instructions under the PCT with effect

•

from 1 July 2002 and 1 January 2004, relating to the composition of the international publication and application numbers and year format for international applications, are now available on the PCT website—see the link from the "New on the PCT website" box on the welcome page or go to:

www.wipo.int/pct/en/texts/index.htm For further information on those modifications, see *PCT Newsletter* Nos. 11/2001 and 06/2002.

PCT PUBLICATIONS

PCT Gazette special issue: General information on Contracting States, national and regional Offices and International Authorities

Consolidated general information relating to PCT Contracting States, national and regional Offices and International Authorities under the PCT will be published in a special issue of the *PCT Gazette* dated 4 July 2002 (No. S-03/2002 (E) (English) and (F) (French)), which replaces the previous special issue containing consoli-

dated general information, published on 10 January 2002 (No. S-01/2002 (E) and (F)). This helpful resource contains the information that is published in Annexes A to E, L and in the National Chapter Summaries of the *PCT Applicant's Guide*.

Subscribers to the *PCT Gazette* automatically receive special issues. If you are not a subscriber to the *PCT Gazette* but would like to obtain that special issue, you may order it from the Marketing and Distribution Section at WIPO:

fax: (41–22) 740 18 12

e-mail: publications.mail@wipo.int

electronic

bookshop: www.wipo.int/ebookshop

mailing

address: see address on cover page

The price per special issue is 24 Swiss francs or 18 US dollars by regular mail, and 28 Swiss francs or 21 US dollars by priority mail. Note that the special issue will also be available in PDF format, free of charge, as part of the *PCT Gazette* on WIPO's Internet site.

| | PCT SEMINAR CALENDAR | | | | | | | |
|---|----------------------|---|---|--|--|--|--|--|
| Dates and Location | Language of seminar | Nature of seminar; WIPO speakers (and others where known) | Organizer and contact numbers | | | | | |
| 15–16 July 2002 Port Louis, Mauritius | English | WIPO National Seminar on Industrial Property and the PCT WIPO speakers: Mr. Sinha and Mr. Farag Other speaker: Mr. Raizada (Ranbaxy Labs, India) | International Trade Division Ministry of Industry and International Trade (Mrs. D. Allagapen) Tel: (230) 201 21 57 Fax: (230) 212 63 68 E-mail: motas@intnet.mu | | | | | |
| 15-16 July 2002 Los Angeles, CA (US) | English | Intermediate PCT seminar for patent attorneys and patent administrators WIPO speaker: Mr. Maassel Other speaker: Mr. Kramer (Pillsbury Winthrop LLP) | American Intellectual Property Law Association (AIPLA) (Ms. Iris Howell) Tel: (1-703) 415 07 80 Fax: (1-703) 415 07 86 E-mail: aipla@aipla.org Internet (for registration): www.aipla.org | | | | | |
| 18-19 July 2002 Toledo, OH (US) | English | Basic PCT seminar for patent attorneys and patent administrators WIPO speaker: [as above] Other speaker: [as above] | [as above] | | | | | |
| 22-23 July 2002 Arlington, VA (US) | English | Advanced PCT seminar for patent attorneys and patent administrators WIPO speaker: [as above] Other speaker: [as above] | [as above] | | | | | |
| 29-30 July 2002 Munich (DE) | German | Basic PCT seminar WIPO speakers: Mr. Reischle and Mrs. Bähr | Forum Institut für Management GmbH Tel: (49–6221) 500 500 Fax: (49–6221) 500 505 E-mail: Management@Forum-Institut.de | | | | | |
| 11-13 August 2002 Washington, D.C. (US) | English | Advanced PCT seminar for patent attorneys WIPO speaker: Mr. Maassel Other speaker: Mr. Reed (The Procter & Gamble Company) | Patent Resources Group, Inc. Tel: (1–804) 296 39 00 Fax: (1–804) 296 39 99 | | | | | |
| 15–17 August 2002 English Washington, D.C. (US) | | Basic PCT seminar for patent attorneys WIPO speaker: [as above] Other speaker: [as above] | Patent Resources Group, Inc. Tel: (1–804) 296 39 00 Fax: (1–804) 296 39 99 | | | | | |

| PCT SEMINAR CALENDAR [continued] | | | | | | |
|--|---|---|---|--|--|--|
| Dates and Location | | | Organizer and contact numbers | | | |
| 5-6 September 2002 Addis Ababa (Ethiopia) | English | WIPO National Seminar on Industrial Property and the PCT WIPO speakers: Mr. Herce-Vigil, Mrs. Simon-Vianes and Mr. Farag | Ethiopian Science and Technology Commission (Mr. Getachew Mengistie) Tel: (251–1) 51 13 44 | | | |
| 11–12 September 2002 Asmara (Eritrea) | English | WIPO National Seminar on Industrial Property and the PCT WIPO speakers: Mr. Herce-Vigil, Mrs. Simon-Vianes and Mr. Farag | Ministry of Trade and Industry (Eritrea) (Mr. Tewolde Woldemichael Deress) Tel: (291–1) 11 51 88/11 78 44 | | | |
| 12-13 September 2002 Geneva (CH) | English | Basic PCT seminar on the PCT system WIPO speakers: to be announced | PCT Legal Division, WIPO (Mrs. Paola Conti Lander) Tel: (41–22) 338 81 93 Fax: (41–22) 910 00 30 Internet (for further information and registration form): www.wipo.int/pct/en/seminar/registration.pdf | | | |
| 16-17 September 2002 Copenhagen (DK) | English | PCT seminar WIPO speakers: Mr. Bryan and Ms. Trpkovska | Centre d'études internationales de la propriété industrielle (CEIPI) and the Danish Patent and Trademark Office (Ms. Inge-Lise Høybye) Tel: (45–43) 50 80 00 Fax: (45–43) 50 80 01 E-mail: pvs@dkpto.dk | | | |
| 8 October 2002 Iselin, New Jersey (US) | English | PCT presentation at the PIUG 2002 Northeast Workshop WIPO speaker: Mr. Maassel | Patent Information Users Group (PIUG) (Ms. Elyse Turner) Tel: (1-732) 594 64 18 Fax: (1-732) 594 58 32 E-mail: elyse_turner@merck.com Internet: www.piug.org/ne02meet.html | | | |
| 8-9 October 2002 Munich (DE) | German | Advanced PCT seminar WIPO speaker: Mr. Reischle Other speaker: Mr. Wolff (European Patent Office) | Forum Institut für Management Gmb Tel: (49–6221) 500 500 Fax: (49–6221) 500 505 E-mail: Management@Forum-Institut. | | | |
| 10 October 2002 Munich (DE) | German | PCT-EASY course WIPO speaker: to be announced | Forum Institut für Management GmbH Tel: (49–6221) 500 500 Fax: (49–6221) 500 505 E-mail: Management@Forum-Institut.de | | | |
| 10 October 2002 Stockholm (SE) | English | PCT presentation at the "Patent Updating Day" seminar WIPO speaker: Mr. Thomas | Swedish Patent Office (Mr. Christer Eklöf) Tel: (46-8) 782 28 32 Fax: (46-8) 783 01 63 E-mail: christer.eklof@prv.se | | | |
| 31 October– 1 November 2002 San Francisco (US) | English | Advanced PCT seminar WIPO speaker(s): to be announced | Intellectual Property International (Ms. Virginia H. Meyer) Tel: (1–415) 289 74 71 Fax: (1–415) 331 60 68 E-mail: IPI@IPISeminars.com Internet: www.ipiseminars.com | | | |
| 4-5 November 2002 Chicago (US) | November 2002 French WIPO speaker(s): to be announced Basic PCT seminar on PCT | | The John Marshall Law School Department of Event Management Tel: (1-312) 987 14 20 Fax: (1-312) 427 71 28 E-mail: Events@jmls.edu | | | |
| 26-27 November 2002 Paris (FR) | | | Institut national de la propriété industrielle (INPI) (Mrs. Christiane Sadrin) Tel: (33–1) 53 04 55 76 Fax: (33–1) 42 93 63 52 | | | |
| 11–12 December 2002 London (GB) | English | PCT seminar: "Advanced PCT Formalities" WIPO speakers: Mr. Reischle and Ms. Trpkovska | Management Forum Ltd Tel: (44-1483) 57 00 99 Fax: (44-1483) 53 64 24 E-mail: josephine.leak@management-forum.co.uk | | | |

MOST FREQUENT PCT USERS*
(applicants with the most international applications published in 2001)

| _ | (applicants with the most international applications published in 2001) | | | | | | | |
|------------|---|----------------------|--------------------------|--|--|--|--|--|
| Rank | Applicant | Country of residence | No. published in 2001 | | | | | |
| 1. | Koninklijke Philips Electronics N.V. | NL | 1,458 | | | | | |
| 2. | Robert Bosch GmbH | DE | 1,170 | | | | | |
| 3. | Siemens Aktiengesellschaft | DE | 1,139 | | | | | |
| 4. | Telefonaktiebolaget LM Ericsson | SE | 876 | | | | | |
| 5. | Matsushita Electric Industrial Co. Ltd. | JP | 852 | | | | | |
| 6. | The Procter & Gamble Company | US | 723 | | | | | |
| 7. | Shanghai Biowindow Gene Development Inc. | CN | 665 | | | | | |
| 8. | Infineon Technologies AG | DE | 527 | | | | | |
| 9. | BASF Aktiengesellschaft | DE | 515 | | | | | |
| 10. | Bayer Aktiengesellschaft | DE | 466 | | | | | |
| 11. | 3M Innovative Properties Company | US | 444 | | | | | |
| 12. | Motorola Inc. | US | 418 | | | | | |
| 13. | Nokia Corporation | FI | 404 | | | | | |
| 14. | General Electric Company | US | 382 | | | | | |
| 15. | Mitsubishi Denki Kabushiki Kaisha | JP | 343 | | | | | |
| 16. | Qualcomm Incorporated | US | 308 | | | | | |
| 10. | Sun Microsystems, Inc. | US | 308 | | | | | |
| 18. | E.I. Du Pont de Nemours and Company | US | 306 | | | | | |
| | Fujitsu Limited | JP | 301 | | | | | |
| 20. | • | JP | 277 | | | | | |
| | Sony Corporation | | | | | | | |
| 21. | Henkel Kommanditgesellschaft auf Aktien | DE | 267 | | | | | |
| 22 | Intel Corporation | US | 267 | | | | | |
| 23. | The Regents of the University of California | US | 266 | | | | | |
| 24. | Corning Incorporated | US | 259 | | | | | |
| 25. | Kimberly-Clark Worldwide, Inc. | US | 246 | | | | | |
| 26. | Unilever plc | GB | 238 | | | | | |
| 27. | Hitachi, Ltd. | JP | 216 | | | | | |
| 28. | AstraZeneca AB | SE | 214 | | | | | |
| 29. | Smithkline Beecham Corporation | US | 205 | | | | | |
| | The Dow Chemical Company | US | 205 | | | | | |
| 31. | Millennium Pharmaceuticals, Inc. | US | 204 | | | | | |
| 32. | Ericsson Inc. | US | 195 | | | | | |
| | Merck Patent GmbH | DE | 195 | | | | | |
| 34. | Honeywell International Inc. | US | 188 | | | | | |
| 35. | Glaxo Group Limited | GB | 187 | | | | | |
| 36. | Advanced Micro Devices, Inc. | US | 185 | | | | | |
| 37. | Japan Science and Technology Corporation | JP | 184 | | | | | |
| 38. | Thomson Licensing S.A. | FR | 181 | | | | | |
| 39. | Shell Internationale Research Maatschappij B.V. | NL | 179 | | | | | |
| 40. | Human Genome Sciences, Inc. | US | 171 | | | | | |
| 41. | Seiko Epson Corporation | JP | 167 | | | | | |
| 42. | Daikin Industries, Ltd. | JP | 166 | | | | | |
| 43. | Nokia Networks Oy | FI | 164 | | | | | |
| 44. | Merck & Co., Inc. | US | 163 | | | | | |
| 77. | Microsoft Corporation | US | 163 | | | | | |
| 16 | • | 03 DE | | | | | | |
| 46. 47. | Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. | | 160 150 | | | | | |
| | Eli Lilly and Company | US | 159 | | | | | |
| 48. | Sony Electronics, Inc. | US | 153 | | | | | |
| 49. | Infineon Technologies North America Corp. | US | 151 | | | | | |
| 50. | Akzo Nobel N.V. | NL | 143 | | | | | |
| 51. | Cognis Deutschland GmbH | DE | 138 | | | | | |
| 52. | Volkswagen Aktiengesellschaft | DE | 127 | | | | | |
| 53. | British Telecommunications Public Limited Company | GB | 126 | | | | | |
| 54. | DSM N.V. | NL | 123 | | | | | |
| 55. | Takeda Chemical Industries, Ltd. | JP | 122 | | | | | |

^{*} The list contains the first-named applicants in 50 or more international applications published in 2001. Note that certain legal entities may be listed separately from other legal entities with which they may be affiliated.

[Most frequent PCT users, continued]

| 57. C 58. C 59. R 60. A 61. C N 63. G 64. C 65. T 66. S 67. M 68. A S 71. A III S 75. C 76. S 77. A F 79. E R 79. E | Novartis AG Commissariat à l'Énergie Atomique Centre National de la Recherche Scientifique (CNRS) Rhodia Chimie Accenture LLP Delphi Technologies Inc. Nokia Mobile Phones Limited Genaissance Pharmaceuticals, Inc. DaimlerChrysler AG Tokyo Electron Limited Sanyo Electric Co., Ltd. Metso Paper, Inc. ABB AB Sciened Life Systems, Inc. Smithkline Beecham plc Applied Materials, Inc. Eastman Chemical Company ncyte Genomics, Inc. Silverbrook Research Pty. Ltd. Curagen Corporation Sony Computer Entertainment Inc. Abbott Laboratories Honeywell Inc. Broadcom Corporation | CH FR FR FR US US FI US DE JP FI SE US GB US US AU US JP US US US | 121 120 118 116 115 111 111 110 108 107 102 100 99 99 99 99 99 98 98 98 98 98 |
|--|--|---|--|
| 58. C 59. F 60. A 61. C N 63. C 64. C 65. T 66. S 67. N 68. A 55. C 71. A F 79. E 79. E | Centre National de la Recherche Scientifique (CNRS) Rhodia Chimie Accenture LLP Delphi Technologies Inc. Nokia Mobile Phones Limited Genaissance Pharmaceuticals, Inc. DaimlerChrysler AG Tokyo Electron Limited Sanyo Electric Co., Ltd. Metso Paper, Inc. ABB AB Sciende Life Systems, Inc. Smithkline Beecham plc Applied Materials, Inc. Eastman Chemical Company ncyte Genomics, Inc. Silverbrook Research Pty. Ltd. Curagen Corporation Sony Computer Entertainment Inc. Abbott Laboratories Honeywell Inc. Broadcom Corporation | FR FR US US FI US DE JP FI SE US GB US US US AU US JP US | 118 116 115 111 111 110 108 107 102 100 99 99 99 99 98 98 98 98 98 |
| 59. F. 60. A 61. C N 63. G 64. C 65. T 66. S 5. T 67. A 68. A 69. T 69. S 77. A 69. S 77. | Rhodia Chimie Accenture LLP Delphi Technologies Inc. Nokia Mobile Phones Limited Genaissance Pharmaceuticals, Inc. DaimlerChrysler AG Tokyo Electron Limited Sanyo Electric Co., Ltd. Metso Paper, Inc. ABB AB Scimed Life Systems, Inc. Smithkline Beecham plc Applied Materials, Inc. Eastman Chemical Company ncyte Genomics, Inc. Silverbrook Research Pty. Ltd. Curagen Corporation Sony Computer Entertainment Inc. Abbott Laboratories Honeywell Inc. Broadcom Corporation | FR US US FI US DE JP FI SE US GB US US US JP US | 116 115 111 111 110 108 107 102 100 99 99 99 99 98 98 98 98 97 |
| 60. A 61. C N 63. G 64. C 65. T 66. S 67. N 68. A S 71. A E III S 75. C 76. S 77. A F 79. E R 82. C | Accenture LLP Delphi Technologies Inc. Nokia Mobile Phones Limited Genaissance Pharmaceuticals, Inc. DaimlerChrysler AG Tokyo Electron Limited Ganyo Electric Co., Ltd. Metso Paper, Inc. ABB AB Scimed Life Systems, Inc. Gmithkline Beecham plc Applied Materials, Inc. Eastman Chemical Company ncyte Genomics, Inc. Gilverbrook Research Pty. Ltd. Curagen Corporation Gony Computer Entertainment Inc. Abbott Laboratories Honeywell Inc. Broadcom Corporation | US US FI US DE JP FI SE US GB US US US US JP US | 115 111 111 110 108 107 102 100 99 99 99 99 98 98 98 98 98 |
| 61. E N 63. G 64. E 65. T 66. S 67. N 68. A S 71. A E III S 75. C 76. S 77. A F 79. E R T 82. C | Delphi Technologies Inc. Nokia Mobile Phones Limited Genaissance Pharmaceuticals, Inc. DaimlerChrysler AG Tokyo Electron Limited Ganyo Electric Co., Ltd. Metso Paper, Inc. ABB AB Geimed Life Systems, Inc. Smithkline Beecham plc Applied Materials, Inc. Eastman Chemical Company ncyte Genomics, Inc. Silverbrook Research Pty. Ltd. Curagen Corporation Gony Computer Entertainment Inc. Abbott Laboratories Honeywell Inc. Broadcom Corporation | US FI US DE JP FI SE US GB US US US JP US AU US JP US | 111 111 110 108 107 102 100 99 99 99 99 98 98 98 98 98 |
| 63. G 64. E 65. T 66. S 67. N 68. A S S 71. A E III S 75. C 76. S 77. A F 79. E R 82. C | Nokia Mobile Phones Limited Genaissance Pharmaceuticals, Inc. DaimlerChrysler AG Tokyo Electron Limited Ganyo Electric Co., Ltd. Metso Paper, Inc. ABB AB Scimed Life Systems, Inc. Smithkline Beecham plc Applied Materials, Inc. Eastman Chemical Company ncyte Genomics, Inc. Silverbrook Research Pty. Ltd. Curagen Corporation Sony Computer Entertainment Inc. Abbott Laboratories Honeywell Inc. Broadcom Corporation | FI US DE JP JP FI SE US GB US US US AU US JP US | 111 110 108 107 102 100 99 99 99 99 98 98 98 98 98 |
| 63. G 64. E 65. T 66. S 67. M 68. A S S 71. A E III S 75. C 76. S 77. A F 79. E R 82. C | Genaissance Pharmaceuticals, Inc. DaimlerChrysler AG Tokyo Electron Limited Sanyo Electric Co., Ltd. Metso Paper, Inc. ABB AB Scimed Life Systems, Inc. Smithkline Beecham plc Applied Materials, Inc. Eastman Chemical Company ncyte Genomics, Inc. Silverbrook Research Pty. Ltd. Curagen Corporation Sony Computer Entertainment Inc. Abbott Laboratories Honeywell Inc. Broadcom Corporation | US DE JP JP FI SE US GB US US US JP US | 110 108 107 102 100 99 99 99 98 98 98 98 98 |
| 64. E 65. T 66. S 67. M 68. A S S 71. A E III S 75. C 76. S 77. A F 79. E | DaimlerChrysler AG Fokyo Electron Limited Sanyo Electric Co., Ltd. Metso Paper, Inc. ABB AB Scimed Life Systems, Inc. Smithkline Beecham plc Applied Materials, Inc. Eastman Chemical Company ncyte Genomics, Inc. Silverbrook Research Pty. Ltd. Curagen Corporation Sony Computer Entertainment Inc. Abbott Laboratories Honeywell Inc. Broadcom Corporation | DE JP JP FI SE US GB US US US JP US | 108 107 102 100 99 99 99 98 98 98 98 98 |
| 65. T 66. S 67. M 68. A S 71. A E III S 75. C 76. S 77. A F 79. E F 82. C | Tokyo Electron Limited Sanyo Electric Co., Ltd. Metso Paper, Inc. ABB AB Scimed Life Systems, Inc. Smithkline Beecham plc Applied Materials, Inc. Eastman Chemical Company ncyte Genomics, Inc. Silverbrook Research Pty. Ltd. Curagen Corporation Sony Computer Entertainment Inc. Abbott Laboratories Honeywell Inc. Broadcom Corporation | JP JP FI SE US GB US US US JP US | 107 102 100 99 99 99 98 98 98 98 98 |
| 66. S 67. M 68. A S S 71. A E III S 75. C 76. S 77. A H 79. E F | Sanyo Electric Co., Ltd. Metso Paper, Inc. ABB AB Scimed Life Systems, Inc. Smithkline Beecham plc Applied Materials, Inc. Eastman Chemical Company ncyte Genomics, Inc. Silverbrook Research Pty. Ltd. Curagen Corporation Sony Computer Entertainment Inc. Abbott Laboratories Honeywell Inc. Broadcom Corporation | JP FI SE US GB US US US AU US JP | 102 100 99 99 99 98 98 98 98 97 |
| 67. M 68. A S S 71. A E III S 75. C 76. S 77. A F 79. E R | Metso Paper, Inc. ABB AB Scimed Life Systems, Inc. Smithkline Beecham plc Applied Materials, Inc. Eastman Chemical Company ncyte Genomics, Inc. Silverbrook Research Pty. Ltd. Curagen Corporation Sony Computer Entertainment Inc. Abbott Laboratories Honeywell Inc. Broadcom Corporation | FI SE US GB US US US US JP US | 100 99 99 99 98 98 98 98 97 |
| 68. ASS SS | ABB AB Scimed Life Systems, Inc. Smithkline Beecham plc Applied Materials, Inc. Eastman Chemical Company ncyte Genomics, Inc. Silverbrook Research Pty. Ltd. Curagen Corporation Sony Computer Entertainment Inc. Abbott Laboratories Honeywell Inc. Broadcom Corporation | SE US GB US US US US AU US JP US | 99 99 99 98 98 98 98 97 |
| 71. A E III S 75. C 76. S 77. A F 79. E F 82. C | Scimed Life Systems, Inc. Smithkline Beecham plc Applied Materials, Inc. Eastman Chemical Company ncyte Genomics, Inc. Silverbrook Research Pty. Ltd. Curagen Corporation Sony Computer Entertainment Inc. Abbott Laboratories Honeywell Inc. Broadcom Corporation | US GB US US US AU US JP US | 99 99 98 98 98 98 97 96 |
| 71. A E III S 75. C 76. S 77. A F 79. E R T 82. C | Smithkline Beecham plc Applied Materials, Inc. Eastman Chemical Company ncyte Genomics, Inc. Silverbrook Research Pty. Ltd. Curagen Corporation Sony Computer Entertainment Inc. Abbott Laboratories Honeywell Inc. Broadcom Corporation | GB US US US AU US JP US | 99 98 98 98 98 97 96 |
| 71. A E III S 75. C 76. S 77. A F 79. E R T 82. C | Smithkline Beecham plc Applied Materials, Inc. Eastman Chemical Company ncyte Genomics, Inc. Silverbrook Research Pty. Ltd. Curagen Corporation Sony Computer Entertainment Inc. Abbott Laboratories Honeywell Inc. Broadcom Corporation | US US US AU US JP US | 98 98 98 98 97 96 |
| 71. A E III S 75. C 76. S 77. A H 79. E R T 82. C | Applied Materials, Inc. Eastman Chemical Company ncyte Genomics, Inc. Silverbrook Research Pty. Ltd. Curagen Corporation Sony Computer Entertainment Inc. Abbott Laboratories Honeywell Inc. Broadcom Corporation | US US AU US JP US | 98 98 98 97 96 |
| 75. C 76. S 77. A 79. E 79. E | Eastman Chemical Company ncyte Genomics, Inc. Silverbrook Research Pty. Ltd. Curagen Corporation Sony Computer Entertainment Inc. Abbott Laboratories Honeywell Inc. Broadcom Corporation | US AU US JP US | 98 98 97 96 |
| 75. C 76. S 77. A 79. E 82. C | ncyte Genomics, Inc. Silverbrook Research Pty. Ltd. Curagen Corporation Sony Computer Entertainment Inc. Abbott Laboratories Honeywell Inc. Broadcom Corporation | US AU US JP US | 98 98 97 96 |
| 75. C 76. S 77. A 79. E 82. C | Silverbrook Research Pty. Ltd. Curagen Corporation Sony Computer Entertainment Inc. Abbott Laboratories Honeywell Inc. Broadcom Corporation | AU US JP US | 98 97 96 |
| 75. C 76. S 77. A F 79. E R 82. C | Curagen Corporation Sony Computer Entertainment Inc. Abbott Laboratories Honeywell Inc. Broadcom Corporation | US JP US | 97 96 |
| 76. S 77. A H 79. E R T 82. C | Sony Computer Entertainment Inc. Abbott Laboratories Honeywell Inc. Broadcom Corporation | JP US | 96 |
| 77. A H 79. E R T 82. C | Abbott Laboratories Honeywell Inc. Broadcom Corporation | US | |
| 79. E R T 82. C | Honeywell Inc. Broadcom Corporation | | 95 |
| 79. E F T 82. C | Broadcom Corporation | | 95 |
| 82. C | | US | 93 |
| 82. C | Raytheon Company | US | 93 |
| 82. C | The Johns Hopkins University | US | 93 |
| - | Continental Teves AG & Co. OHG | DE | 92 |
| OO. II | biden Co., Ltd. | JP | 91 |
| | PPG Industries Ohio, Inc. | US | 91 |
| | Société des Produits Nestlé S.A. | CH | 91 |
| | | US | 90 |
| | Massachusetts Institute of Technology | US | |
| | Pharmacia & Upjohn Company | | 90 |
| | Samsung Electronics Co., Ltd. | KR | 90 |
| | Nortel Networks Limited | CA | 88 |
| | The Government of the United States of America, represented by the Secretary, Department of Health and Human Services | US | 88 |
| Z | ZF Friedrichshafen AG | DE | 88 |
| 92. Is | sis Pharmaceuticals, Inc. | US | 87 |
| L | _'Oréal | FR | 87 |
| 94. A | Asahi Kasei Kabushiki Kaisha | JP | 86 |
| 95. L | Jnilever N.V. | NL | 85 |
| 96. C | Ciba Specialty Chemicals Holding Inc. | СН | 84 |
| Т | Teijin Limited | JP | 84 |
| 98. G | Gemplus | FR | 83 |
| K | Kabushiki Kaisha Toshiba | JP | 83 |
| | AlliedSignal Inc. | US | 82 |
| | California Institute of Technology | US | 82 |
| | Exxonmobil Research and Engineering Company | US | 82 |
| | Sarnoff Corporation | US | 78 |
| | _exmark International, Inc. | US | 77 |
| _ | Bristol-Myers Squibb Company | US | 76 |
| | Zymogenetics, Inc. | US | 76 |
| | Lam Research Corporation | US | 75 |
| | Medtronic, Inc. | US | 75 75 |
| | SSH Bosch und Siemens Hausgeräte GmbH | DE | 74 |
| | Warner-Lambert Company | US | 74 74 |

[Most frequent PCT users, continued]

| Rank | Applicant | Country of residence | No. published in 2001 |
|------|--|----------------------|-----------------------|
| 111. | Alcatel | FR | 73 |
| | Hamamatsu Photonics K. K. | JP | 73 |
| | Mitsui Chemicals, Inc. | JP | 73 |
| 114. | France Télécom | FR | 72 |
| | Ortho-McNeil Pharmaceutical, Inc. | US | 72 |
| 116. | Advanced Cardiovascular Systems, Inc. | US | 71 |
| | Kaneka Corporation | JP | 71 |
| 440 | Seagate Technology LLC | US | 71 |
| 119. | F. Hoffmann-La Roche AG | CH | 70 |
| | Kao Corporation | JP | 70 |
| | MCI WorldCom, Inc. | US | 70 |
| 100 | Milliken & Company | US | 70 |
| 123. | BASF Coatings AG | DE | 68 |
| 105 | Fudan University | CN | 68 |
| 125. | | US | 67 |
| 107 | Sharp Kabushiki Kaisha | JP | 67 |
| 127. | | FR | 66 |
| 120 | Genentech Inc. | US | 66 |
| 129. | , | JP GB | 65 65 |
| | BAE Systems plc Biodoor Gene Technology Ltd. Shanghai | CN | 65 |
| | | US | 65 65 |
| | Lexicon Genetics Incorporated Nec Corporation | JP | 65 65 |
| | Wisconsin Alumni Research Foundation | US | 65 |
| 135 | Aventis Pharma Deutschland GmbH | DE | 64 |
| 133. | Aventis Pharma S.A. | FR | 64 |
| | Board of Regents, the University of Texas System | US | 64 |
| 138. | Idemitsu Petrochemical Co., Ltd. | JP | 63 |
| | Novo Nordisk A/S | DK | 63 |
| | Novozymes A/S | DK | 63 |
| 141. | Asahi Glass Company, Limited | JP | 62 |
| | Kyowa Hakko Kogyo Co. Ltd. | JP | 62 |
| | Sumitomo Electric Industries, Ltd. | JP | 62 |
| 144. | Micron Technology, Inc. | US | 61 |
| | QinetiQ Limited | GB | 61 |
| 146. | Hyseq, Inc. | US | 60 |
| | Koenig & Bauer Aktiengesellschaft | DE | 60 |
| | Sanofi-Synthélabo | FR | 60 |
| | The Board of Trustees of the Leland Stanford Junior University | US | 60 |
| | The General Hospital Corporation | US | 60 |
| 151. | ABB Research Ltd. | СН | 59 |
| | Alcon Universal Ltd. | CH | 59 |
| | Cardiac Pacemakers, Inc. | US | 59 |
| | Corixa Corporation | US | 59 |
| | Lockheed Martin Corporation | US | 59 |
| | Shin-Etsu Handotai Co., Ltd. | JP | 59 |
| | Syngenta Participations AG | CH | 59 |
| 158. | Colgate-Palmolive Company | US | 58 |
| | Halliburton Energy Services, Inc. | US | 58 |
| | Honda Giken Kogyo Kabushiki Kaisha | JP | 58 |
| | Owens Corning | US | 58 |
| | Schering Aktiengesellschaft | DE | 58 |
| 163. | Baxter International Inc. | US | 57 |
| | Bioroad Gene Development Ltd. Shanghai | CN | 57 |
| | Bridgestone Corporation | JP [continued] | 57 |

[Most frequent PCT users, continued]

| Rank | Applicant | Country of residence | No. published in 2001 |
|------|--|----------------------|-----------------------|
| | Chiron Corporation | US | 57 |
| | Conexant Systems, Inc. | US | 57 |
| | Toray Industries, Inc. | JP | 57 |
| 169. | International Business Machines Corporation | US | 56 |
| | Nikon Corporation | JP | 56 |
| 1 | Nippon Sheet Glass Co., Ltd. | JP | 56 |
| | The Trustees of Columbia University in the City of New York | US | 56 |
| 173. | Nippon Steel Corporation | JP | 55 |
| 174. | Schott Glas | DE | 54 |
| | The Penn State Research Foundation | US | 54 |
| 176. | Amgen Inc. | US | 53 |
| | Ebara Corporation | JP | 53 |
| | Isis Innovation Limited | GB | 53 |
| | Showa Denko K.K. | JP | 53 |
| 180. | Allergan Sales, Inc. | US | 52 |
| | Hewlett-Packard Company | US | 52 |
| | L'Air Liquide, Société Anonyme pour l'Étude et l'Exploitation des Procédés | | |
| | Georges Claude | FR | 52 |
| | Mobil Oil Corporation | US | 52 |
| 184. | · · · · · · · · · · · · · · · · · · · | US | 51 |
| | Chugai Seiyaku Kabushiki Kaisha | JP | 51 |
| | Phillips Petroleum Company | US | 51 |
| 187. | BASF Corporation | US | 50 |
| | Pharmacia Corporation | US | 50 |
| | Schlumberger Technology Corporation | US | 50 |
| | The Gillette Company | US | 50 |

MOST FREQUENT PCT USERS* (applicants with the most international applications published in 2001) (by alphabetical order of applicants' names)

| Rank | Applicant | Country of residence | No. published in 2001 |
|------|---------------------------------------|----------------------|-----------------------|
| 11. | 3M Innovative Properties Company | US | 444 |
| 68. | ABB AB | SE | 99 |
| 151. | ABB Research Ltd. | CH | 59 |
| 77. | Abbott Laboratories | US | 95 |
| 60. | Accenture LLP | US | 115 |
| 116. | Advanced Cardiovascular Systems, Inc. | US | 71 |
| 36. | Advanced Micro Devices, Inc. | US | 185 |
| 129. | Ajinomoto Co., Inc. | JP | 65 |
| 50. | Akzo Nobel N.V. | NL | 143 |
| 111. | Alcatel | FR | 73 |
| 151. | Alcon Universal Ltd. | CH | 59 |
| 180. | Allergan Sales, Inc. | US | 52 |
| 100. | AlliedSignal Inc. | US | 82 |
| 176. | Amgen Inc. | US | 53 |
| 71. | Applied Materials, Inc. | US | 98 |
| 141. | Asahi Glass Company, Limited | JP | 62 |
| 94. | Asahi Kasei Kabushiki Kaisha | JP | 86 |
| 28. | AstraZeneca AB | SE | 214 |
| 127. | Atofina | FR | 66 |
| 135. | Aventis Pharma Deutschland GmbH | DE | 64 |
| 135. | Aventis Pharma S.A. | FR | 64 |
| 184. | Avery Dennison Corporation | US | 51 |
| 129. | BAE Systems plc | GB | 65 |

^{*} The list contains the first-named applicants in 50 or more international applications published in 2001. Note that certain legal entities may be listed separately from other legal entities with which they may be affiliated.

[Most frequent PCT users (alphabetical order), continued]

| Rank | Applicant | Country of residence | No. published in 2001 |
|------|--|----------------------|-----------------------|
| 9. | BASF Aktiengesellschaft | DE | 515 |
| 123. | BASF Coatings AG | DE | 68 |
| 187. | BASF Corporation | US | 50 |
| 163. | Baxter International Inc. | US | 57 |
| 10. | Bayer Aktiengesellschaft | DE | 466 |
| 129. | Biodoor Gene Technology Ltd. Shanghai | CN | 65 |
| 163. | Bioroad Gene Development Ltd. Shanghai | CN | 57 |
| 135. | Board of Regents, the University of Texas System | US | 64 |
| 163. | Bridgestone Corporation | JP | 57 |
| 105. | Bristol-Myers Squibb Company | US | 76 |
| 53. | British Telecommunications Public Limited Company | GB | 126 |
| 79. | Broadcom Corporation | US | 93 |
| 109. | BSH Bosch und Siemens Hausgeräte GmbH | DE | 74 |
| 100. | California Institute of Technology | US | 82 |
| 151. | 5 , | US | 59 |
| 58. | Centre National de la Recherche Scientifique (CNRS) | FR | 118 |
| 163. | Chiron Corporation | US | 57 |
| 184. | Chugai Seiyaku Kabushiki Kaisha | JP | 51 |
| 96. | Ciba Specialty Chemicals Holding Inc. | CH | 84 |
| 51. | Cognis Deutschland GmbH | DE | 138 |
| 158. | Colgate-Palmolive Company | US | 58 |
| 57. | , , , | FR | 120 |
| 163. | Conexant Systems, Inc. | US | 57 |
| 82. | Continental Teves AG & Co. OHG | DE | 92 |
| 151. | Corixa Corporation | US | 59 |
| 24. | • | US | 259 |
| 75. | Curagen Corporation | US | 97 |
| 42. | Daikin Industries, Ltd. | JP | 166 |
| 64. | DaimlerChrysler AG | DE | 108 |
| 61. | Delphi Technologies Inc. | US | 111 |
| 54. | DSM N.V. | NL | 123 |
| - | | US | 306 |
| | E.I. Du Pont de Nemours and Company Eastman Chemical Company | US | 98 |
| | • • | JP | |
| | Ebara Corporation | US | 53 |
| 47. | Eli Lilly and Company | | 159 |
| 32. | Ericsson Inc. | US | 195 |
| | Exxonmobil Research and Engineering Company | US | 82 |
| | F. Hoffmann-La Roche AG | CH | 70 |
| 114. | France Télécom | FR | 72 |
| 46. | Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. | DE | 160 |
| 123. | Fudan University | CN | 68 |
| | Fujitsu Limited | JP | 301 |
| | Gemplus | FR | 83 |
| 63. | Genaissance Pharmaceuticals, Inc. | US | 110 |
| 127. | Genentech Inc. | US | 66 |
| 14. | General Electric Company | US | 382 |
| 125. | General Instrument Corporation | US | 67 |
| 35. | Glaxo Group Limited | GB | 187 |
| 158. | Halliburton Energy Services, Inc. | US | 58 |
| 111. | Hamamatsu Photonics K. K. | JP | 73 |
| 21. | Henkel Kommanditgesellschaft auf Aktien | DE | 267 |
| 180. | Hewlett-Packard Company | US | 52 |
| 27. | Hitachi, Ltd. | JP | 216 |
| 158. | Honda Giken Kogyo Kabushiki Kaisha | JP | 58 |
| 77. | Honeywell Inc. | US | 95 |

[Most frequent PCT users (alphabetical order), continued]

| | Henry well interpolitional los | | in 2001 |
|------|--|----|---------|
| 40 | Honeywell International Inc. | US | 188 |
| 40. | Human Genome Sciences, Inc. | US | 171 |
| 146. | Hyseq, Inc. | US | 60 |
| 83. | Ibiden Co., Ltd. | JP | 91 |
| 138. | Idemitsu Petrochemical Co., Ltd. | JP | 63 |
| 71. | Incyte Genomics, Inc. | US | 98 |
| 8. | Infineon Technologies AG | DE | 527 |
| 49. | Infineon Technologies North America Corp. | US | 151 |
| 21. | Intel Corporation | US | 267 |
| 169. | International Business Machines Corporation | US | 56 |
| 176. | Isis Innovation Limited | GB | 53 |
| 92. | Isis Pharmaceuticals, Inc. | US | 87 |
| 37. | Japan Science and Technology Corporation | JP | 184 |
| 98. | Kabushiki Kaisha Toshiba | JP | 83 |
| 116. | Kaneka Corporation | JP | 71 |
| | Kao Corporation | JP | 70 |
| | Kimberly-Clark Worldwide, Inc. | US | 246 |
| | Koenig & Bauer Aktiengesellschaft | DE | 60 |
| | Koninklijke Philips Electronics N.V. | NL | 1,458 |
| | Kyowa Hakko Kogyo Co. Ltd. | JP | 62 |
| | L'Air Liquide, Société Anonyme pour l'Étude et l'Exploitation des Procédés Georges Claude | FR | 52 |
| 107. | Lam Research Corporation | US | 75 |
| | Lexicon Genetics Incorporated | US | 65 |
| | Lexmark International, Inc. | US | 77 |
| | Lockheed Martin Corporation | US | 59 |
| | L'Oréal | FR | 87 |
| | Massachusetts Institute of Technology | US | 90 |
| | Matsushita Electric Industrial Co. Ltd. | JP | 852 |
| | MCI WorldCom, Inc. | US | 70 |
| 107. | Medtronic, Inc. | US | 75 |
| | Merck & Co., Inc. | US | 163 |
| 32. | Merck Patent GmbH | DE | 195 |
| _ | | FI | 100 |
| | Metso Paper, Inc. | | |
| | Micron Technology, Inc. | US | 61 |
| | Microsoft Corporation | US | 163 |
| | Millennium Pharmaceuticals, Inc. | US | 204 |
| | Milliken & Company | US | 70 |
| | Mitsubishi Denki Kabushiki Kaisha | JP | 343 |
| 111. | Mitsui Chemicals, Inc. | JP | 73 |
| 180. | Mobil Oil Corporation | US | 52 |
| 12. | Motorola Inc. | US | 418 |
| | Nec Corporation | JP | 65 |
| | Nikon Corporation | JP | 56 |
| 169. | Nippon Sheet Glass Co., Ltd. | JP | 56 |
| 173. | Nippon Steel Corporation | JP | 55 |
| | Nokia Corporation | FI | 404 |
| | Nokia Mobile Phones Limited | FI | 111 |
| | Nokia Networks Oy | FI | 164 |
| 89. | Nortel Networks Limited | CA | 88 |
| 56. | Novartis AG | CH | 121 |
| 138. | Novo Nordisk A/S | DK | 63 |
| 138. | Novozymes A/S | DK | 63 |
| 114. | Ortho-McNeil Pharmaceutical, Inc. | US | 72 |
| | Owner Coming | US | 58 |
| 158. | Owens Corning | 03 | 50 |

[Most frequent PCT users (alphabetical order), continued]

| Rank | Applicant | Country of residence | No. published in 2001 |
|-------------|--|----------------------|-----------------------|
| 187. | Pharmacia Corporation | US | 50 |
| 184. | Phillips Petroleum Company | US | 51 |
| 83. | PPG Industries Ohio, Inc. | US | 91 |
| 144. | QinetiQ Limited | GB | 61 |
| 16. | Qualcomm Incorporated | US | 308 |
| 79. | Raytheon Company | US | 93 |
| 59. | Rhodia Chimie | FR | 116 |
| 2. | Robert Bosch GmbH | DE | 1,170 |
| 86. | Samsung Electronics Co., Ltd. | KR | 90 |
| 146. | Sanofi-Synthélabo | FR | 60 |
| 66. | Sanyo Electric Co., Ltd. | JP | 102 |
| 103. | Sarnoff Corporation | US | 78 |
| 158. | Schering Aktiengesellschaft | DE | 58 |
| 187. | Schlumberger Technology Corporation | US | 50 |
| 174. | Schott Glas | DE | 54 |
| 68. | Scimed Life Systems, Inc. | US | 99 |
| 116. | Seagate Technology LLC | US | 71 |
| 41. | Seiko Epson Corporation | JP | 167 |
| 7. | Shanghai Biowindow Gene Development Inc. | CN | 665 |
| 125. | Sharp Kabushiki Kaisha | JP | 67 |
| 39. | Shell Internationale Research Maatschappij B.V. | NL | 179 |
| 151. | Shin-Etsu Handotai Co., Ltd. | JP | 59 |
| 176. | Showa Denko K.K. | JP | 53 |
| 3. | Siemens Aktiengesellschaft | DE | 1,139 |
| 71. | Silverbrook Research Pty. Ltd. | AU | 98 |
| 29. | Smithkline Beecham Corporation | US | 205 |
| 68. | Smithkline Beecham plc | GB | 99 |
| 83. | Société des Produits Nestlé S.A. | CH | 91 |
| 76. | Sony Computer Entertainment Inc. | JP | 96 |
| 20. | Sony Corporation | JP | 277 |
| 48. | Sony Electronics, Inc. | US | 153 |
| 141. | Sumitomo Electric Industries, Ltd. | JP | 62 |
| 16. | Sun Microsystems, Inc. | US | 308 |
| 151. | Syngenta Participations AG | CH | 59 |
| 55. | Takeda Chemical Industries, Ltd. | JP | 122 |
| 96. | Teijin Limited | JP | 84 |
| 4. | Telefonaktiebolaget LM Ericsson | SE | 876 |
| 146. | The Board of Trustees of the Leland Stanford Junior University | US | 60 |
| 29. | The Dow Chemical Company | US | 205 |
| 146. | The General Hospital Corporation | US | 60 |
| 187. | The Gillette Company | US | 50 |
| 89. | The Government of the United States of America, represented by the Secretary, | | |
| 70 | Department of Health and Human Services | US | 88 |
| 79. | The Johns Hopkins University | US | 93 |
| 174. | The Penn State Research Foundation | US | 54 |
| 6. | The Procter & Gamble Company The Proceed of the University of Colifornia | US | 723 |
| 23. | The Regents of the University of California The Trustees of Calumbia University in the City of New York | US US | 266 56 |
| 169. 38. | The Trustees of Columbia University in the City of New York | FR | 56 181 |
| 65. | Thomson Licensing S.A. | JP | 107 |
| | Tokyo Electron Limited | | |
| 163. | Toray Industries, Inc. Unilever N.V. | JP NI | 57 |
| 95. | | NL GB | 85 |
| 26. 52 | Unilever plc | | 238 |
| 52. | Volkswagen Aktiengesellschaft Warner Lambert Company | DE | 127 74 |
| 109. | Warner-Lambert Company Wisconsin Alumni Research Foundation | US US | 74 65 |
| 129. 89. | ZF Friedrichshafen AG | DE | 65 |
| | | | 88 76 |
| 105. | Zymogenetics, Inc. | US | 76 |

PCT FEE TABLES

The following Tables show the amounts and currencies of the main PCT fees which are payable to the receiving Offices (ROs) and the International Preliminary Examining Authorities (IPEAs) during the international phase under Chapter I (Tables I(a) and I(b)) and under Chapter II (Table II). Fees which are payable only in particular circumstances are not shown; nor are details of certain reductions and refunds which may be available; such information can be found in the *PCT Applicant's Guide*, Vol. I/B, Annexes C, D and E. Note that all amounts are subject to change due to variations in the fees themselves or fluctuations in exchange rates. The total amount of the basic fee and designation fee may be reduced by CHF 200 under certain circumstances where the request is prepared using the PCT-EASY software; see footnote 2 for details. A 75% reduction in the basic fee, the fee per sheet over 30, the designation fee and the handling fee, as well as an exemption from the transmittal fee payable to the International Bureau as receiving Office, is also available to applicants from certain States; see footnote 12 for details. (Note that if both the CHF 200 reduction and the 75% reduction are applicable, the 75% reduction is calculated *after* the CHF 200 reduction.) The footnotes to the Fee Tables follow Table II.

Key to abbreviations used in fee tables:

|) | | | | | | | | | |
|-------|---------------------------|-----|------------------------|-----|-------------------|-----|--------------------|-----|---------------------|
| eq | equivalent of | BGL | Bulgarian lev | GEL | Georgian Iari | LTL | Lithuanian litas | SGD | Singapore dollar |
| IPEA | International Preliminary | BRR | Brazilian real | GHC | Ghanaian cedi | LVL | Latvian lat | SIT | Slovenian tolar |
| | Examining Authority | BYR | Belarussian rouble | HRK | Croatian kuna | MAD | Moroccan dirham | SKK | Slovak koruna |
| ISA | International Searching | BZD | Belize dollar | HUF | Hungarian forint | MDL | Moldovan leu | TJS | Tajik somoni |
| | Authority | CAD | Canadian dollar | IDR | Indonesian rupiah | MKD | Macedonian denar | TND | Tunisian dinar |
| n a | not applicable | CHF | Swiss franc | ILS | New Israel shekel | MWK | Malawian kwacha | TTD | Trinidad and Tobago |
| RO | receiving Office | CNY | Yuan renminbi | INR | Indian rupee | MXP | Mexican peso | | dollar |
| | - | CUP | Cuban convertible peso | ISK | Icelandic krona | NOK | Norwegian krone | UAH | Ukrainian hryvnia |
| Curre | ncies: | CYP | Cyprus pound . | JPY | Japanese yen | NZD | New Zealand dollar | USD | US dollar |
| AED | United Arab Emirates | CZK | Czech koruna | KES | Kenyan shilling | PHP | Philippine peso | VND | Vietnamese dong |
| | dirham | DKK | Danish krone | KGS | Kyrgyz som | PLZ | Polish zloty | YUD | Yugoslavian dinar |
| ALL | Albanian lek | DZD | Algerian dinar | KPW | KP won | ROL | Romanian leu | ZAR | South African rand |
| AMD | Armenian dram | EEK | Estonian kroon | KRW | KR won | RUR | Russian rouble | ZWD | Zimbabwe dollar |
| AUD | Australian dollar | EUR | Euro | KZT | Kazakh tenge | SDP | Sudanese pound | | |
| AZM | Azerbaijani manat | GBP | Pound sterling | LSM | Lesotho loti | SEK | Swedish krona | | |
| | | | | | | | | | |

Table I(a) — TRANSMITTAL, BASIC AND DESIGNATION FEES

(as at 1 July 2002, unless otherwise indicated)

| RO | Transmittal fee ¹ | | | sic fee ^{1,2,3} SHF 650) | Fee per sheet over 30 ^{1,2,3,4} (CHF 15) | Designation fee ^{1,2,3,5,6} (CHF 140) | PCT-EASY reduction ² (CHF 200) | Competent ISA(s) ⁷ |
|----|------------------------------|-----------------|---------|--------------------------------------|---|--|---|----------------------------------|
| AE | AED ⁸ | _ | AED ed | CHF 650 | 15 | 140 | n a | AT AU |
| AL | ALL | 9,000 | CHF | 650 | 15 | 140 | n a | EP |
| AM | AMD | 32,000 | USD | 407 | 9 | 88 | 125 | EP RU |
| AP | USD | 50 | USD | 407 | 9 | 88 | 125 | AT EP SE |
| | (or eq in local | currency) | | | | | | |
| AT | EUR | 50 | EUR | 444 | 10 | 96 | 137 | EP |
| AU | AUD | 100 | AUD | 746 | 17 | 161 | 230 | AU |
| ΑZ | AZM eq USD | 15 | USD | 407 | 9 | 88 | n a | EP RU |
| | plus mailing co | | | | | | | |
| BA | EUR | 25.56 | EUR | 444 | 10 | 96 | 137 | EP |
| BE | EUR | 40 | EUR | 444 | 10 | 96 | 137 | EP |
| BG | BGL | 60 | BGL | eq CHF 650 | eq CHF 15 | eq CHF 140 | eq CHF 200 | EP RU |
| BR | BRR | 236 | BRR | eq CHF 650 | eq CHF 15 | eq CHF 140 | eq CHF 200 | AT EP SE US |
| BY | BYR eq USD | 70 | USD | 407 | 9 | 88 | n a | EP RU |
| BZ | BZD | 220 | USD | 407 | 9 | 88 | 125 | EP |
| CA | CAD | 200 | CAD | 639 | 15 | 138 | 197 | EP |
| СН | CHF | 100 | CHF | 650 | 15 | 140 | 200 | EP |
| CN | CNY | 500 | CNY | eq CHF 650 | eq CHF 15 | eq CHF 140 | eq CHF 200 | CN |
| CR | USD | 175 | USD | 407 | 9 | 88 | 125 | EP ES |
| cu | USD (or eq C | UP) 200 | USD (or | eq CUP) 407 | 9 | 88 | 125 | AT EP ES RU |
| CY | CYP | 75 | CYP | 258 | 6 | 56 | n a | EP |
| CZ | CZK | 1,500 | CZK | eq CHF 650 | eq CHF 15 | eq CHF 140 | eq CHF 200 | EP |

..., ____

Table I(a) — TRANSMITTAL, BASIC AND DESIGNATION FEES [continued] (as at 1 July 2002, unless otherwise indicated)

| RO | Transmittal fee ¹ | | ransmittal fee ¹ Basic fee ^{1,2,3} (CHF 650) | | Fee per sheet over 30 ^{1,2,3,4} | Designation fee ^{1,2,3,5,6} | PCT-EASY reduction ² | Competent ISA(s) ⁷ |
|----------|------------------------------|-------------------|--|--------------------|--|--------------------------------------|---------------------------------|-------------------------------|
| | | | | | (CHF 15) | (CHF 140) | (CHF 200) | |
| DE | EUR | 90 | EUR | 444 | 10 | 96 | 137 | EP |
| DK | DKK | 1,500 | DKK | 3,300 | 80 | 710 | 1,020 | EP SE |
| DZ | DZD ⁸ | _ | CHF | 650 | 15 | 140 | 200 | AT EP |
| EA | RUR eq U | SD 50 | USD | 407 | 9 | 88 | 125 | EP RU |
| EC | USD ⁸ | _ | USD | 407 | 9 | 88 | 125 | EP ES |
| EE | EEK | 1,800 | EEK | eq CHF 650 | eq CHF 15 | eq CHF 140 | eq CHF 200 | EP |
| EP | EUR | 100 | EUR | 444 | 10 | 96 | 137 | EP |
| ES | EUR | 61.51 | EUR | 444 | 10 | 96 | 137 | EP ES |
| FI | EUR | 135 | EUR | 444 | 10 | 96 | 137 | EP SE |
| FR | EUR | 60 | EUR | 444 | 10 | 96 | 137 | EP |
| GB | GBP | 55 | GBP | 278 | 6 | 60 | 86 | EP |
| GE | GEL ⁹ | 10 | USD | 407 | 9 | 88 | 125 | EP RU |
| GH | GHC ¹⁰ | 2,500 or 5,000 | USD | 407 | 9 | 88 | n a | AT AU CN EP SE |
| GR | EUR | 115 | EUR | 444 | 10 | 96 | 137 | EP |
| HR | HRK | 200 | HRK | eq C HF 650 | eq CHF 15 | eq CHF 140 | eq CHF 200 | EP |
| HU | HUF ¹¹ | 10,000 | HUF | eq CHF 650 | eq CHF 15 | eq CHF 140 | eq CHF 200 | EP RU |
| IB | CHF ¹² | 100 | CHF | 650 | 15 | 140 | 200 | See footnote 13 |
| | or USD ¹² | 60 | or USD | 407 | 9 | 88 | 125 | ALL ED DIL |
| ID IE | IDR EUR | 500,000 | IDR | eq CHF 650 | eq CHF 15 | eq CHF 140 | eq CHF 200 | AU EP RU EP |
| IL | ILS | 76.00 445 | EUR USD | 444 407 | 10 9 | 96 88 | 137 125 | EP US |
| IN | INR | 5,000 | USD | 407 | 9 | 88 | 125 | AT AU CN EP SE US |
| 114 | (filing by in | | 030 | 407 | 7 | 00 | 123 | AT AU CIVEF SE US |
| IS | ISK | 5,500 | ISK | 41,300 | 1,000 | 8,900 | 11,600 | EP SE |
| IT | EUR | 30.99 | EUR | 444 | 10 | 96 | n a | EP |
| JP | JPY | 18,000 | JPY | 47,800 | 1,100 | 10,300 | 14,700 | EP JP |
| KE | USD (or KES plus cost of | ' ' | USD | 407 | 9 | 88 | 125 | AT AU CN EP SE |
| KG | KGS eq US | SD 100 | USD | 407 | 9 | 88 | 125 | EP RU |
| KP | KPW eq C | HF 50 | KPW | eq CHF 650 | eq CHF 15 | eq CHF 140 | eq CHF 200 | AT RU |
| KR | KRW | 45,000 | KRW | 530,000 | 12,000 | 114,000 | 163,000 | AT AU JP ¹⁴ KR |
| KZ | KZT ⁸ | _ | USD | 407 | 9 | 88 | 125 | EP RU |
| LR | USD | 45 | USD | 407 | 9 | 88 | na | AT AU CN EP SE |
| LS | LSM ⁸ | _ | LSM | eq CHF 650 | eq CHF 15 | eq CHF 140 | n a | AT EP |
| LT | LTL | 320 | USD | 407 | 9 | 88 | na | EP RU |
| LU | EUR | 19 | EUR | 444 | 10 | 96 | n.a. | EP |
| LV | LVL | 47.20 | USD | 407 | 9 | 88 | 125 | EP RU |
| MA | | None | CHF | 650 | 15 | 140 | n a | AT EP RU SE |
| MC | EUR | 49 | EUR | 444 | 10 | 96 | n a | EP |
| MD | MDL | 180 | USD | 407 | 9 | 88 | 125 | EP RU |
| MK | MKD | 2,750 | MKD | eq CHF 650 | eq CHF 15 | eq CHF 140 | eq CHF 200 | EP |
| MN | | None | CHF | 650 | 15 | 140 | 200 | EP RU |
| MW | MWK | 2,000 | MWK | 25,000 | 600 | 5,400 | 7,700 | EP |

Table I(a) — TRANSMITTAL, BASIC AND DESIGNATION FEES [continued]

(as at 1 July 2002, unless otherwise indicated)

| RO | Transmittal fee ¹ | | | | | | Bas (C | ic fee ^{1,2,3} HF 650) | Fee per sheet over 30 ^{1,2,3,4} (CHF 15) | Designation fee ^{1,2,3,5,6} (CHF 140) | PCT-EASY reduction ² (CHF 200) | Competent ISA(s) ⁷ |
|----|------------------------------|---------------|-----------------|---------------------------------------|--------------------|-----------------------|-------------------------|------------------------------------|---|--|---|----------------------------------|
| MX | MXP ³ eq USD | 200 | MXP | eq CHF 650 | eq CHF 15 | eq CHF 140 | eq CHF 200 | EP ES SE US | | | | |
| NL | EUR | 50 | EUR | 444 | 10 | 96 | 137 | EP | | | | |
| NO | NOK | 500 | NOK | 3,560 | 80 | 770 | 1,090 | EP SE | | | | |
| NZ | NZD | 180 | NZD | 890 | 20 | 192 | 274 | AU EP US | | | | |
| OM | Information not | yet available | | | | | | | | | | |
| PH | PHP | 3,500 | USD | 407 | 9 | 88 | 125 | AU EP JP KR US | | | | |
| PL | PLZ | 300 | PLZ | eq CHF 650 | eq CHF 15 | eq CHF 140 | n a | EP | | | | |
| PT | EUR | 23.19 | EUR | 444 | 10 | 96 | 137 | EP | | | | |
| RO | ROL | 300,000 | CHF | 650 | 15 | 140 | 200 | AT EP RU | | | | |
| RU | RUR | 294 | USD | 407 | 9 | 88 | 125 | EP RU | | | | |
| SD | SDP | 50 | SDP | eq CHF 650 | eq CHF 15 | eq CHF 140 | n a | EP | | | | |
| SE | SEK | 1,200 | SEK | 4,390 | 100 | 950 | 1,350 | EP SE | | | | |
| SG | SGD | 150 | SGD | 720 | 17 | 156 | 222 | AT AU EP | | | | |
| SI | SIT | 22,000 | SIT | eq CHF 650 | eq CHF 15 | eq CHF 140 | eq CHF 200 | EP | | | | |
| SK | SKK | 1,600 | SKK | eq CHF 650 | eq CHF 15 | eq CHF 140 | eq CHF 200 | EP | | | | |
| TJ | TJS ₈ | _ | USD | 407 | 9 | 88 | n a | EP RU | | | | |
| TM | USD ⁸ | _ | USD | 407 | 9 | 88 | 125 | EP RU | | | | |
| TN | TND ⁸ | _ | CHF | 650 | 15 | 140 | n a | EP | | | | |
| TR | CHF | 100 | CHF | 650 | 15 | 140 | 200 | EP | | | | |
| TT | TTD | 750 | USD | 407 | 9 | 88 | 125 | AT EP SE US | | | | |
| UA | UAH | 255 | USD | 407 | 9 | 88 | n a | EP RU | | | | |
| US | USD | 240 | USD | 407 | 9 | 88 | 125 | EP US | | | | |
| UZ | USD ⁸ | _ | USD | 407 | 9 | 88 | 125 | EP RU | | | | |
| VN | VND eq USD | 150 | VND | eq CHF 650 | eq CHF 15 | eq CHF 140 | n a | AT AU EP RU SE | | | | |
| YU | YUD | 3,000 | YUD | eq CHF 650 | eq CHF 15 | eq CHF 140 | eq CHF 200 | EP | | | | |
| ZA | ZAR | 500 | ZAR (from 1. | 4,870 <i>8.02:</i> 4, <i>240</i>) | 112 <i>(98)</i> | 1,050 <i>(910)</i> | 1,500 <i>(1,300)</i> | AT AU EP US | | | | |
| ZM | Information not | yet available | | | | | | | | | | |
| ZW | ZWD | 1,000 | ZWD | eq USD 407 | eq USD 9 | eq USD 88 | eq USD 125 | AT AU CN EP RU | | | | |

Table I(b) — SEARCH FEES (as at 1 July 2002, unless otherwise indicated)

| ISA | | | | | | Searc | ch fee ¹ | | | | | |
|-------------------------|-------------------|--|-----------------------|-----------------------------------|------------------------|--------------------------|---------------------|--------------|--------------|----------------|------------|--------------|
| AT | EUR | 159 | CHF | 230 | KRW | 191,000 | SGD | 259 | USD | 150 | ZAR | 1,280 |
| AU | AUD ZAR | 800 4,290 | CHF *(from | 697 n <i>1.8.02:KRl</i> | KRW* W 568,00 | 500,000 <i>0)</i> | NZD | 978 | SGD | 700 | USD | 393 |
| CN | CNY | 1,500 | CHF | 290 | USD | 180 | | | | | | |
| EP ¹⁵ | EUR ISK SGD | 945 83,000 1,533 | CAD JPY USD | 1,360 110,000 866 | CHF MWK ZAR | 1,383 53,000 9,450 | CYP NOK* | 550 7,570 | DKK NZD** | 7,030 2,023 | GBP SEK | 592 8,720 |
| | | rom 15.8.02: rom 15.7.02: | NOK NZD | 7,070) 1,889) | | | | | | | | |
| ES ¹⁵ | EUR | 945 | CHF | 1,383 | USD | 866 | | | | | | |
| JP | JPY | 72,000 | CHF | 980 | KRW | 798,000 | USD | 535 | | | | |
| KR | KRW | 150,000 | CHF | 180 | USD | 120 | | | | | | |
| RU ¹⁶ | USD | 300 | CHF | 480 | | | | | | | | |
| SE | SEK 8, USD86 | 720 CHF 6* <i>(from 15.8</i> | 1,383 . <i>02:</i> | DKK <i>NOK</i> | 7,030 <i>7,070)</i> | EUR | 945 | ISK | 83,000 | NOK* | 7,570 | |
| US | USD70 | 0 450 ¹⁷ | CHF | 1,118 | 719 1/ | NZD | 1,590 | 1,020 17 | ZAR* | 8,000 | 5,200 1/ | |
| | * (fi | rom 1.9.02: | | ZAR | 7,000 | 4,500 ¹⁷ | <i>'</i>) | | | | | |

Table II — PRELIMINARY EXAMINATION FEES

(as at 1 July 2002, unless otherwise indicated)

| IPEA | | Prelimi | nary examination fee ¹⁸ | | Handling fee ³ | ^{3,18} (CHF 233) | |
|-------------------------|-----|-------------------|------------------------------------|-----------|---------------------------|---------------------------|--|
| AT | EUR | 159 | | EUR | 159 | | |
| AU | AUD | 450 | | AUD | 267 | | |
| CN | CNY | 1,500 | | CNY eq CH | F 233 | | |
| EP ¹⁵ | EUR | 1,530 | | EUR | 159 | | |
| JP | JPY | 28,000 | | JPY | 17,100 | | |
| KR | KRW | 150,000 | | KRW | 190,000 | | |
| RU ¹⁶ | USD | 200 ¹⁹ | 300 ²⁰ | USD | 146 | | |
| SE | SEK | 5,000 | | SEK | 1,570 | | |
| US | USD | 490 | 750 ²¹ | USD | 146 | | |

Footnotes to fee tables:

- 1 Payable to the receiving Office in the currency or one of the currencies prescribed by it.
- 2 The total amount of the basic fee and designation fee is reduced by 200 Swiss francs where: (a) the request is presented as a computer print-out prepared using the PCT-EASY software; (b) the request is filed together with a computer diskette, prepared using that software, containing a copy in electronic form of the data contained in the request and of the abstract; and (c) the PCT application is filed with a receiving Office which is prepared to accept the filing of PCT applications containing requests in PCT-EASY format together with PCT-EASY diskettes.
- 3 This fee is reduced by 75% where the applicant or, if there are two or more applicants, each applicant is a natural person and is a national of and resides in Albania, Algeria, Armenia, Azerbaijan, Belarus, Belize, Benin, Bosnia and Herzegovina, Brazil, Bulgaria, Burkina Faso, Cameroon, Central African Republic, Chad, China, Colombia, Congo, Costa Rica, Côte d'Ivoire, Croatia, Cuba, Čzech Republic, Democratic People's Republic of Korea, Dominica, Ecuador, Equatorial Guinea, Estonia, Gabon, Gambia, Georgia, Ghana, Grenada, Guinea, Guinea-Bissau, Hungary, India, Indonesia, Kazakhstan, Kenya, Kyrgyzstan, Latvia, Lesotho, Liberia, Lithuania, Madagascar, Malawi, Mali, Mauritania, Mexico, Mongolia, Morocco, Mozambique, Niger, Philippines, Poland, Republic of Moldova, Romania, Russian Federation, Saint Lucia, Senegal, Sierra Leone, Slovakia, South Africa, Sri Lanka, Sudan, Swaziland, Tajikistan, The former Yugoslav Republic of Macedonia, Togo, Tunisia, Turkey, Turkmenistan, Uganda, Ukraine, United Republic of Tanzania, Uzbekistan, Viet Nam, Yugoslavia, Zambia or Zimbabwe. For further details, see *PCT Newsletter* No. 10/1995, cover page, No. 11/1995, page 6, and No. 05/1996, cover page.
- 4 Where the PCT application as filed contains a sequence listing part in computer readable form only, or both in that form and on paper, under Section 801 of the PCT Administrative Instructions, and where that application is filed with a receiving Office which is prepared to accept such filings, a fixed component of 400 times the fee per sheet over 30 is payable for the sequence listing part, irrespective of the actual length of that part (see Section 803(ii) of the Administrative Instructions).
- 5 The maximum number of designation fees payable is five.
- 6 The confirmation fee payable under PCT Rules 4.9(c) and 15.5 is 50% of the designation fee due (taking into account any applicable 75% reduction; see footnote 3)
- 7 For the search fee payable to the receiving Office, consult the entry in Table I(b) for the competent International Searching Authority
- 8 The amounts are not yet known or, where known, are subject to periodical revision. The Office or the agent should be consulted for the latest applicable schedule of fees.
- 9 This fee is reduced by 80% where the applicant is a natural person.
- 10 The first amount of the transmittal fee is applicable to individuals or entities employing less than 25 persons. The second amount is applicable to entities employing 25 persons or more.
- 11 A supplement of HUF 500 is also payable for each claim in excess of 10.
- 12 This fee is not payable in respect of international applications filed by applicants fulfilling the conditions indicated in footnote 3.
- 13 The competent International Searching Authority(ies) for an international application filed with the International Bureau as receiving Office is (are) the Authority(ies) which would have been competent if the international application had been filed with the receiving Office of, or acting for, the Contracting State of which the applicant (or any of the applicants) is a resident or national. See also PCT Applicant's Guide, Vol. I/B, Annex C (IB).
- 14 The Japan Patent Office is competent only for international applications in Japanese.
- 15 The search fee payable to the EPO and the Spanish Patent and Trademark Office, as well as the preliminary examination fee payable to the EPO, are reduced by 75% where the applicant or, if there are two or more applicants, each applicant is a natural person and is a national of and resides in a State not party to the European Patent Convention, which fulfils the requirements for the corresponding reduction of certain PCT fees as specified in the Schedule of Fees annexed to the PCT Regulations, and in accordance with the decision of the EPO 's Administrative Council of 11 October 2000, the text of which was included in *PCT Newsletter* No. 11/2000. The States concerned are those indicated in footnote 3, with the exception of Bulgaria, the Czech Republic, Estonia, Slovakia and Turkey.
- 16 The applicant may, instead of paying the USD amount, pay the equivalent amount in RUR at the exchange rate applicable, on the date of payment, at the Central Bank of the Russian Federation, provided that, in the case of the search fee, the receiving Office accepts payment in RUR.

 17 Payable when a corresponding prior US national application has been filed under 35 USC 111(a) and the basic filing fee for that US
- application has been paid.
- 18 Payable to the International Preliminary Examining Authority in the currency or one of the currencies prescribed by it.
- 19 Payable when the international search report was established by the Russian Patent Office.
- 20 In all cases where footnote 19 does not apply.
- 21 Payable when the international search was not carried out by the United States Patent and Trademark Office (USPTO) (provided that the USPTO is a competent International Preliminary Examining Authority in the particular case-see PCT Applicant's Guide, Vol. I/B, Annex C.)

PCT CONTRACTING STATES AND TWO-LETTER CODES (116 on 1 July 2002)



| ΑE | United Arab | CO | Colombia | ID | Indonesia | MK | The former | SZ | Swaziland (AP) ² |
|----|---------------------------------|----|---------------------------------|----|--------------------------|----|-------------------------------|----|-----------------------------|
| | Emirates | CR | Costa Rica | ΙE | Ireland (EP)2 | | Yugoslav Republic | | Chad (OA)2 ' |
| AG | Antigua and | CU | Cuba | IL | Israel | | of Macedonia ¹ | TG | Togo (OA) ² |
| | Barbuda | CY | Cyprus (EP) ² | IN | India | ML | Mali (OA) ² | | Tajikistan (EA) |
| ΑL | Albania ¹ | | Czech Repúblic | IS | Iceland | MN | Mongolia | | Turkmenistan (EA) |
| AM | Armenia (EA) | DE | Germany (EP) | ΙT | Italy (EP)2 | MR | Mauritania (OA) ² | | Tunisia |
| | Austria (ÈP) | | Denmark (EP) | JΡ | Japan | MW | Malawi (AP) | TR | Turkey (EP) |
| | Australia | DM | Dominica` ´ | ΚE | Kenya (AP) | MX | Mexico | TT | Trinidad and |
| ΑZ | Azerbaijan (EA) | DΖ | Algeria | KG | Kyrgyzstan (EA) | ΜZ | Mozambique (AP) | | Tobago |
| | Bosnia and ` | EC | Ecuador | ΚP | Democratic | NE | Niger (OA) ² | ΤZ | United Republic of |
| | Herzegovina | Œ | Estonia | | People's Republic | NL | Netherlands (EP) ² | | Tanzania (AP) |
| BB | Barbados | ES | Spain (EP) | | of Korea | NO | Norway | UΑ | Ukraine ` ´ |
| BE | Belgium (EP) ² | FI | Finland (EP) | KR | Republic of Korea | ΝZ | New Zealand | UG | Uganda (AP) |
| BF | Burkina Faso (OA)2 | FR | France (EP)2 | | Kazakhstan (EA) | OM | Oman | US | United States of |
| BG | Bulgaria | GΑ | Gabon (OA) ² | LC | Saint Lucia | PH | Philippines | | America |
| BJ | Benin (OA) ² | GB | United Kingdom (EP) | LI | Liechtenstein (EP) | PL | Poland | UΖ | Uzbekistan |
| BR | Brazil | GD | Grenada | LK | Sri Lanka | PT | Portugal (EP) | VC | Saint Vincent and |
| BY | Belarus (EA) | Œ | Georgia | LR | Liberia | RO | Romania ¹ | | the Grenadines |
| ΒZ | Belize | GH | Ghana (AP) | LS | Lesotho (AP) | RU | Russian | | (from 6 August |
| CA | Canada | GM | Gambia (AP) | LT | Lithuania1 | | Federation (EA) | | 2002) |
| CF | Central African | GN | Guinea (OA)2 | LU | Luxembourg (EP) | SD | Sudan (AP) | ٧N | Viet Nam |
| | Republic (OA) ² | GQ | Equatorial | LV | Latvia ¹ | SE | Sweden (EP) | ΥU | Yugoslavia |
| CG | Congo (OA) ² | | Guinea (OA) ² | MΑ | Morocco | SG | Singapore | ZΑ | South Africa |
| CH | Switzerland (EP) | GR | Greece (EP)2 | MC | Monaco (EP) ² | SI | Slovenia ¹ | ZM | Zambia (AP) |
| CI | Côte d'Ivoire (OA) ² | GW | Guinea-Bissau (OA) ² | MD | Republic of | SK | Slovakia | ZW | Zimbabwe (AP) |
| CM | Cameroon (OA) ² | HR | Croatia | | Moldova (EA) | SL | Sierra Leone (AP) | | |
| CN | China | HU | Hungary | MG | Madagascar | SN | Senegal (OA) ² | | |

1 Extension of European patent possible.

Where a State can be designated for a regional patent, the two-letter code for the regional patent concerned is indicated in parentheses (AP = ARIPO patent, EA = Eurasian patent, EP = European patent, OA = OAPI patent).

Important:

This list includes all States that have adhered to the PCT by the date shown in the heading. Any State indicated in **bold italics** has adhered to the PCT but was not yet bound by the PCT on the date of issue of the latest version of the request form. Where any State has adhered to but is not yet bound by the PCT, the date on which it will become bound is shown in parentheses; it cannot be designated in international applications filed before that date. If the applicant wishes to designate, for the purposes of a national patent, any State which is bound by the PCT on the date on which the international application is filed but which is not listed in the request form, he must add it in Box No. V of the request form and mark the corresponding check-hox.

Applicants should always use the latest versions of the request form (PCT/RO/101) and demand form (PCT/IPEA/401), updated versions of which are normally issued twice yearly. The latest versions are dated July 2002. The forms are reproduced in Annexes X and Y, respectively, in Vol. I/B of the *PCT Applicant's Guide* (July 2002 update), and can be printed from the WIPO Internet site, in editable PDF format, at: http://www.wipo.int/pct/en/forms/index.htm, or obtained from receiving Offices or the International Bureau, or, in the case of the demand form, also from International Preliminary Examining Authorities.

² May only be designated for a regional patent (the "national route" via the PCT has been closed).